Literature DB >> 16267613

Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer.

Karolina Przybylowska1, Anita Kluczna, Marek Zadrozny, Tadeusz Krawczyk, Andrzej Kulig, Jan Rykala, Agnieszka Kolacinska, Zbigniew Morawiec, Jozef Drzewoski, Janusz Blasiak.   

Abstract

PURPOSE: Matrix metalloproteinases play a crucial role in the cancer invasion and metastasis, angiogenesis and tumorigenicity. A single guanine insertion--the 1G/2G polymorphism in the promoter of the matrix metalloproteinase 1 (MMP-1) gene creates a binding site for the transcription factor AP-1 and thus may affect the transcription level of MMP-1. The C-->T substitution at the polymorphic site of the MMP-9 gene promoter results in a higher transcription activity of the T-allelic promoter trough the loss of binding site for a repressor protein. The aim of this work was to investigate the influence of 1G/2G and C-->T polymorphisms on the MMP-1 and MMP-9 level and therefore on the occurrence and progression of breast cancer. EXPERIMENTAL
DESIGN: We investigated the distribution of genotypes and frequency of alleles of the 1G/2G and C-->T polymorphisms for 270 patients with breast cancer and 300 healthy women served as control. The genotypes were determined by RFLP-PCR. Additionally, we estimated the level of MMP-1 and MMP-9 antigens in tumor samples and normal breast tissue using ELISA.
RESULTS: The levels of MMP-1 in tumor samples of node positive patients ware significantly higher than in samples of node negative patients (p<0.05). Increased level of MMP-9 correlates with Bloom-Richardson grading III (p<0.05), increased tumor size (p<0.05) and absence of estrogen and progesterone receptors (p<0.01). Additionally, both MMP-1 and MMP-9 levels were higher in tumor than in the normal breast tissue. We showed the higher risk of metastasis development in lymph node for the 2G/2G genotype (OR=2.14; CI 95% 1.24;3.69) and the 2G allele carriers (OR=1.68; CI 95% 1.19;2.39). We found correlation between the T allele (OR=2.61; CI 95% 1.33;4.87), 2G (OR=2.58; CI 95% 1.35;4.91) and malignance.
CONCLUSION: The results suggest that MMP-1 is responsible for the local invasion and MMP-9 is associated with the malignance and the growth of the tumor. We suggest that the 2G allele of the 1G/2G MMP-1 gene polymorphism may be associated with the lymph node metastasis in patients with breast cancer and therefore it can be considered as a progression marker in this disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267613     DOI: 10.1007/s10549-005-9042-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  44 in total

1.  The polymorphism MMP1 -1607 (1G>2G) is associated with a significantly increased risk of cancers from a meta-analysis.

Authors:  Lili Lu; Yujiao Sun; Yiqun Li; Ping Wan
Journal:  Tumour Biol       Date:  2014-11-13

2.  Analysis of matrix metalloproteinase-1 gene polymorphisms and expression in benign and malignant breast tumors.

Authors:  Jing Zhou; Constance Brinckerhoff; Susan Lubert; Kui Yang; Jasmine Saini; Jeffrey Hooke; Richard Mural; Craig Shriver; Stella Somiari
Journal:  Cancer Invest       Date:  2011-11       Impact factor: 2.176

3.  What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?

Authors:  Ferdinando Mannello
Journal:  BMC Med       Date:  2011-08-11       Impact factor: 8.775

4.  MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study.

Authors:  Alicia Beeghly-Fadiel; Wei Lu; Xiao-Ou Shu; Jirong Long; Qiuyin Cai; Yongbin Xiang; Yu-Tang Gao; Wei Zheng
Journal:  Breast Cancer Res Treat       Date:  2010-08-20       Impact factor: 4.872

5.  Gelatinase B (-1562C/T) polymorphism in tumor progression and invasion of breast cancer.

Authors:  P Chiranjeevi; K Mrudula Spurthi; N Santhoshi Rani; G Rajesh Kumar; T Mohini Aiyengar; M Saraswati; G Srilatha; G Kishore Kumar; Sudha Sinha; C Sanjeeva Kumari; B Nagarjuna Reddy; S Vishnupriya; H Surekha Rani
Journal:  Tumour Biol       Date:  2013-12-20

6.  Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case-control study.

Authors:  Fawziya Abd Elmaogoud Ragab Ibrahim; Shaymaa Essam Elfeky; Medhat Haroun; Mohamed Abd Elrahman Ahmed; Mostafa Elnaggar; Nada Abd Elfatah Ismail; Nadia Ahmed Abd El Moneim
Journal:  Mol Clin Oncol       Date:  2020-05-05

7.  Functional polymorphisms of matrix metalloproteinase-9 and survival in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.

Authors:  Huai Liu; Pei-Yu Huang; Lin-Quan Tang; Qiu-Yan Chen; Ying Zhang; Lu Zhang; Ling Guo; Dong-Hua Luo; Hao-Yuan Mo; Yan-Qun Xiang; Fang Qiu; Rui Sun; Ming-Yuan Chen; Yi-Jun Hua; Xing Lv; Lin Wang; Chong Zhao; Xiang Guo; Ka-Jia Cao; Chao-Nan Qian; Ming-Huang Hong; Hai-Qiang Mai
Journal:  Med Oncol       Date:  2013-08-18       Impact factor: 3.064

8.  Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma.

Authors:  Li-E Wang; Yu-jing Huang; Ming Yin; Jeffrey E Gershenwald; Victor G Prieto; Jeffrey E Lee; Madeleine Duvic; Elizabeth A Grimm; Qingyi Wei
Journal:  Eur J Cancer       Date:  2010-07-23       Impact factor: 9.162

9.  Matrix Metalloproteinase-9 (MMP9)-A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric Disorders.

Authors:  Janusz K Rybakowski
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-31

10.  Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature.

Authors:  Andrea Köhrmann; Ulrike Kammerer; Michaela Kapp; Johannes Dietl; Jelena Anacker
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.